Figure 1

1
Supplementary Figure 1 Histological staging
criteria for acute GvHD   Hepatic GVHD 1. Minimal
periductal lymphoid cell infiltrates (5-10
cells) 2. Mild periductal lymphoid cell
infiltrates (10-20 cells) 3. Moderate periductal
lymphoid cell infiltrates (20-40 cells), with
intraepithelial lymphoid cells, single cell
hepatocellular necrosis 4. Moderate to severe
periductal lymphoid cell infiltrates (gt40 cells),
with intraepithelial lymphoid cells single cell
hepatocellular necrosis some bridging of
portal zones with lymphoid infiltrates   Gastric
GVHD 1. Squamous portion - small numbers of
lymphocytes adjacent to basal epithelium 2.
Squamous portion - small number of lymphocytes
adjacent to basal epithelium and small numbers of
intraepithelial lymphocytes glandular portion
-intraepithelial lymphocytes with
degeneration of Parietal cells 3. Squamous
portion - small to moderate number of lymphocytes
adjacent to basal epithelium and small to
moderate numbers of intraepithelial lymphocytes
glandular portion - intraepithelial
lymphocytes with prominent degeneration of
Parietal cells 4. Squamous portion - small to
moderate number of lymphocytes adjacent to basal
epithelium and small to moderate numbers of
intraepithelial lymphocytes glandular
portion - intraepithelial lymphocytes with
prominent degeneration of Parietal cells mucosal
erosion/ulceration   Intestinal GVHD 1. Minimal
to small numbers of infiltrating lymphocytes into
crypt epithelium rare degenerative epithelial
cells 2. Small numbers of infiltrating
lymphocytes into crypt epithelium increased
numbers of mitoses rare to small numbers of
degenerative epithelial cells in some crypts 3.
Larger numbers of infiltrating lymphocytes into
crypt epithelium increased numbers of mitoses
small numbers of degenerative epithelial cells
in most crypts /- mucosal ulceration 4.
Larger numbers of infiltrating lymphocytes into
crypt epithelium increased numbers of mitoses
most crypts have evidence of degeneration of
crypt epithelial cells /- mucosal
ulceration   Cutaneous GVHD 1. multifocal mild
epidermal hyperplasia and hypekeratosis, minimal
numbers of intraepithelial lymphocytes 2.
multifocal mild epidermal hyperplasia and
hypekeratosis, small numbers of intraepithelial
lymphocytes, and rare degenerated epithelial
cells 3. multifocal mild to moderate epidermal
hyperplasia and hypekeratosis, small to moderate
numbers of intraepithelial lymphocytes, and small
to moderate numbers of degenerated
epithelial cells 4. multifocal moderate
epidermal hyperplasia and hypekeratosis, moderate
numbers of intraepithelial lymphocytes, and
moderate numbers of degenerated epithelial
cells, microabscesses, skin erosion and/or
ulceration
2
Supplementary Figure 2 Ruxolitinib does not
impair post-transplant donor myeloid
reconstitution and full donor chimerism.
a
b
pNS
2,0




1,5
Donor Ter119 cells (103)/ul blood
1,0
pNS
0,5






pNS



0
Day 14 post- BMT
Day 30 post- BMT
c
d
p0.01






pNS



3
Supplementary Figure 3 GVT effect against
myeloid leukemia RMB-1 cell line is maintained in
the presence of ruxolitinib
a
b
4

Supplementary Figure 4 Ruxolitinib at the dose
of 90 mg/Kg prevents acute GVHD without affecting
T cell alloreactivity
a
b
a
b

100
120
100
75
80
Spleen T cells
Cells per Spleen (106)
60
50
NS
40
NS
NS
25
20
0
0
Total Spleen cells
CD3 cells
CD4 cells
CD8 cells
Naive T (CD62LCD44-)
CM T (CD62LCD44)
EM T (CD62L-CD44)
c
p0.06
p0.07
p0.3

p0.2

Spleen CD4IFN-? cells
Spleen CD8IFN-? cells
d
e
p0.3
p0.3
1.5
1.0
Spleen Treg cells
Spleen CD4IL-17 cells
0.5
0
0
5
Supplementary Figure 5 Ruxolitinib effect at 45
mg/Kg on absolute numbers of alloreactive T
cells, Th17 and Treg cells.
a
b
c
6
Supplementary Figure 6 Representative Images of
Ruxolitinb effect on T cells and macrophage
infiltration of GVHD organs
b
a
c